Bausch + Lomb Discontinues BL1107 Eye Drops After 159-Patient Phase 2 Failure, Shifts to GA Implant
BLCO•Phase 2 trial of BL1107 in 159 glaucoma patients failed to meet its primary endpoint of change in visual field mean deviation after 28 days. Bausch + Lomb will discontinue the topical eye drop program and focus on its Whitecap-acquired sustained-release implant for geographic atrophy, with trials slated for 2028.
1. Phase 2 Trial Outcomes
Phase 2 trial of BL1107 enrolled 159 adults with primary open-angle glaucoma or ocular hypertension in a randomized, double-masked, three-arm study. After 28 days of topical dosing, the study failed to achieve its primary endpoint of change in visual field mean deviation and did not meet key secondary visual function endpoints, though intraocular pressure reduction was observed and the safety profile remained consistent.
2. Strategic Pipeline Shift
Based on the trial results, Bausch + Lomb will discontinue development of BL1107 as a topical eye drop and reallocate resources to its sustained-release implant program targeting geographic atrophy. The implant candidate was acquired in 2025 via the Whitecap Biosciences acquisition and is being developed in collaboration with Ripple Therapeutics, leveraging a polymer-free controlled-release platform.
3. Pipeline and Milestones
Bausch + Lomb’s pipeline comprises over 60 active development assets spanning Consumer, Pharmaceuticals, Surgical and Vision Care segments. The company anticipates multiple clinical, regulatory and commercial milestones in the coming months and plans to initiate clinical trials of the GA sustained-release implant in 2028.
